Market revenue in 2023 | USD 2,045.2 million |
Market revenue in 2030 | USD 7,177.1 million |
Growth rate | 19.6% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 74.89% in 2023. Horizon Databook has segmented the South Korea precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea is the 12th largest market in the healthcare industry. The South Korean government has planned to invest more than USD 1.7 billion in the country's biotechnology and biopharmaceutical sector. The country is one of the key markets for regenerative medicine as it was the first to commercialize stem cell therapy.
The Korean government is also supportive of the adoption of gene therapy products. For instance, in 2019, the government passed the Act on the Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals, which allows conditional approval for the commercial sale of phase II completed drugs.
Such favorable government initiatives are expected to accelerate the growth of gene therapy market. Furthermore, Samsung Biologics is a leading South Korean company that operates in this space. The company has entered into several collaborations and partnerships for manufacturing gene therapy products.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into South Korea precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account